Association of low-dose glucocorticoid use and infection occurrence in systemic lupus erythematosus patients: a prospective cohort study.

Kazuya AbeYuichi IshikawaYasuhiko KitaNobuyuki YajimaEisuke InoueKen-Ei SadaYoshia MiyawakiRyusuke YoshimiYasuhiro ShimojimaShigeru OhnoHiroshi KajiyamaKunihiro IchinoseShuzo SatoMichio Fujiwara

Published in: Arthritis research & therapy (2022)

Our results suggested that the use of 5.0-7.5 mg PSL or equivalent could pose an infection risk in SLE patients. This finding indicates that PSL dose should be reduced to as low as possible in SLE patients to avoid infection.

Keyphrases

end stage renal disease
low dose
ejection fraction
newly diagnosed
chronic kidney disease
systemic lupus erythematosus
peritoneal dialysis
prognostic factors
risk assessment
patient reported outcomes
high dose